StemCell Institute EBIT

The latest EBIT for 7096.T is $180M as of June 2026. That compares with $370M in the prior-year period — down 50.4% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside StemCell Institute's historical trend and sector peers before judging valuation or financial health.

Over the past year, 7096.T's EBIT moved from $370M to $180M — a 50.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in StemCell Institute's operating scale or balance-sheet position.

Against Healthcare companies, 7096.T currently prints $180M for EBIT, while the sector average sits near $110B. That is roughly 99.8% below the sector mean. Large gaps often invite a closer look at StemCell Institute's growth, margins, and balance sheet.

A EBIT figure of $180M for 7096.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting 7096.T's EBIT ($180M), review year-over-year change from $370M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.